News
Public · Published
Oruka's Psoriasis Treatment Could Generate $7B In Peak Sales, Says Guggenheim – ORKA Stock Heads For Best Day In Over 4 Months
Oruka Therapeutics said its Phase 2b trial of an experimental psoriasis treatment showed about 61% of patients on the highest 600 mg dose had completely clear symptoms after week 16, versus none on placebo. Guggenheim reaffirmed its bullish view, and the stock rose over 13%.
Published:
Updated:
What happened
Oruka Therapeutics said its Phase 2b trial of an experimental psoriasis treatment showed about 61% of patients on the highest 600 mg dose had completely clear symptoms after week 16, versus none on placebo. Guggenheim reaffirmed its bullish view, and the stock rose over 13%.
Confirmed
Global impact / market context
Strong trial results and a supportive analyst view can raise expectations that the treatment will reach the market and sell well. Guggenheim's $7 billion peak sales estimate, which means projected yearly revenue at its height, suggests investors see a large commercial opportunity.
Analyst inference
The stock jumped over 13%, broke above its 50-day moving average, which means a common trend line tracked by traders, and headed for its best day since June. That suggests investors were repositioning toward the shares after the data.
Analyst inference
What to watch
- Oruka plans to engage with regulatory agencies and start Phase 3 trials of ORKA-001 in the first half of next year, a later and larger stage of testing needed before approval. Confirmed
- Guggenheim's $7 billion peak sales projection is an analyst estimate, not a company forecast, so watch whether future trial data and eventual pricing support that figure. Proposed
- Watch whether the trial's strong symptom-clearing results hold in larger Phase 3 testing, since a smaller mid-stage study can overstate how well a treatment performs. Analyst inference